Highlights by Tom Powles from ASCO GU25
At ASCO GU 2025, Professor Tom Powles, Professor at the University of London, highlighted key advancements in genitourinary cancer treatment, including novel immunotherapy combinations and precision medicine approaches.
His insights provide a glimpse into the future of cancer care. Here’s a quick summary of his key takeaways:
1. “New FGFR3 specific TKI is FGFR altered advanced UC.
Confirmed ORR was 41% with attractive toxicity profile.
This maybe best combed with other therapies.”
2. “COSMIC313:Cabo/ipi/nivo vs ipi/nivo in mRCC.
RR + PFS +ve but OS HR =1.02.
Triplet tolerability is harder.
Are we plateauing in RCC drug development? M2 data looks similar to the myeloid data in atezo vs atezo/bev (VEGF overcome IO resistance).
More RCC biomarker progress.”
3. “5 year & final results for 9ER Cabo/nivo vs sunitinib shows consistent results with other VEGF/IO combos.
RR,PFS & OS HRs=56%, 0.58 & 0.79. OS benefit in good vs int/poor risk:1.08 vs 0.74.
No activity difference in sites of mets, such as bone.
Pick one use it well.”
4. “SAMETA: the 1st biomarker driven R3 papillary RCC study.
CALYPSO is the phase 2 data supporting it.
RR PFS and OS in the MET driven group looks promising for durva/savolitinib.
Francesca Jackson also presents baseline and dynamic ctDNA analysis.
A new biomarker in PRCC?”
5. “The combos of pembrolizumab/belzutifan or lenvatinib/belzutifab were tested against Len/pem in pretreated advanced RCC.
These new combos are in R3 trials.
Len/bel looks perhaps more active.
Belzutifan/pem is being tested earlier in the adjuvant setting vs pembro alone.”
6. “KIM-1, linked to immune biology, appears the best prognosis biomarker for kidney cancer.
A decrease at 3 wks is higher for sunitinib than ipi/nivo but the fall predicts responses to ipi/nivo only.
We should start exploring this circulating marker for prognosis and immune therapy.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023